Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.31 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 6/20 | 0.31 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.31 |
| ▸ | LIPC | P11150 | 2/20 | 0.31 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.31 |
| ▸ | ACACB | O00763 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.30 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.30 |
| ▸ | RBP4 | P02753 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3575973 | 0.91 | CYP3A4 (0.42) | CYP3A4PIM1PIM3PIM2KCNH2 | |
| SCHEMBL3590136 | 0.88 | CYP3A4 (0.35) | CYP3A4PIM1PIM3PIM2DRD2 | |
| SCHEMBL3577931 | 0.78 | KCNH2 (0.33) | CYP3A4KCNH2DRD2LIPCLIPG | |
| SCHEMBL3578342 | 0.76 | MEN1 (0.35) | DRD2DRD3 | |
| SCHEMBL482753 | 0.74 | CYP3A4 (0.72) | CYP3A4KCNH2 | |
| SCHEMBL3590072 | 0.73 | CYP3A4 (0.57) | CYP3A4KCNH2 | |
| SCHEMBL2078715 | 0.71 | CYP3A4 (0.70) | CYP3A4KCNH2 | |
| SCHEMBL2078716 | 0.71 | CYP3A4 (0.70) | CYP3A4KCNH2 | |
| SCHEMBL2268507 | 0.67 | NPFFR1 (0.48) | — | |
| SCHEMBL5768492 | 0.67 | NPFFR1 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100069435-A1 | METHOD OF SELECTIVELY INTRODUCING AMINO SUBSTITUENT | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2010-03-18 | — | — | US | disclosed |
| US-7626029-B2 | Into a difluorobenzoic acid, for producting quinolonecarboxylic acid serving as synthetic antibacterial agent, medicament, agricultural chemical, or veterinary drug; ionic liquid solvents | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-12-01 | — | — | US | disclosed |
| US-20060122396-A1 | Method of selectively introducing amino substituent | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-06-08 | — | — | US | disclosed |
| EP-1634879-A1 | METHOD OF SELECTIVELY INTRODUCING AMINO SUBSTITUENT | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-03-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122396-A1 | Method of selectively introducing amino substituent | ASNS, NQO2, DDC | CYP3A4 300/4885PIM1 2755/4885PIM3 2597/4885 |
| US-20100069435-A1 | METHOD OF SELECTIVELY INTRODUCING AMINO SUBSTITUENT | ASNS, DDC, NQO2 | CYP3A4 140/4885PIM1 2504/4885PIM3 2201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.